{Reference Type}: Journal Article
{Title}: Macrophage Activation Syndrome in the Setting of Rheumatic Diseases.
{Author}: Chatham WW;
{Journal}: Adv Exp Med Biol
{Volume}: 1448
{Issue}: 0
{Year}: 2024
{Factor}: 3.65
{DOI}: 10.1007/978-3-031-59815-9_27
{Abstract}: Patients with established rheumatic disorders may develop complications of macrophage activation syndrome due to severe flares of the underlying disease (adult-onset Still's disease, SLE); however, in most other rheumatic disorders, MAS develops in association with identified viral or other infectious triggers. It is therefore important to pursue appropriate studies to identify potential infectious triggers in rheumatic disease patients who develop MAS. Management is best directed toward treatment of the triggering infections and combinations of high-dose corticosteroids, calcineurin inhibitors, and biologic therapies targeting IL-1 and/or IL-6 to suppress the associated cytokine storm.